You Are Here    News

News
Few people with HIV starting raltegravir and dolutegravir change therapy because of side-effects
by Michael Carter, 2017-07-21 08:10
Only a few people starting an integrase inhibitor discontinue the treatment during the first year of therapy due to drug-related toxicities, investigators from Switzerland report in an advance online publication in the journal AIDS. The prospective study monitored over 4000 HIV-positive people who started treatment with raltegravir or dolutegravir between 2006 and 2015. Side-effects leading

US regulators approves Gilead's Vosevi combo pill for hepatitis C re-treatment
by Liz Highleyman, 2017-07-19 18:40
On July 18 the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" for people with all hepatitis C virus (HCV) genotypes who were not previously cured with prior direct-acting antiviral (DAA) therapy. Vosevi

US regulators approves Gilead's Vosevi combo pill for hepatitis C retreatment
by Liz Highleyman, 2017-07-19 18:40
On 18 July the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" for people with all hepatitis C virus (HCV) genotypes who were not previously cured with prior direct-acting antiviral (DAA) therapy. Vosevi

US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment
by Liz Highleyman, 2017-07-19 18:40
On 18 July the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" for people with all hepatitis C virus (HCV) genotypes who were not previously cured with prior direct-acting antiviral (DAA) therapy. Vosevi

Many people living with HIV at high risk of cardiovascular disease are not on statins
by Michael Carter, 2017-07-19 12:10
Only half of HIV-positive patients at a Chicago clinic eligible for statin therapy according to the latest US guidelines are receiving this treatment, investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The researchers say their findings raise concerns about sub-optimal cardiovascular disease prevention among people living with HIV.The

People treated with atazanavir had lower risk of stroke and heart attack
by Keith Alcorn, 2017-07-18 12:20
People who started HIV treatment with a drug combination containing atazanavir (Reyataz) were significantly less likely to suffer a heart attack or stroke than people starting treatment with other regimens, a large study of US military veterans has found. The findings are published are published in advance online in the journal

Gay men using HIV self-tests promptly seek confirmatory testing and linkage to care, New York data suggests
by Roger Pebody, 2017-07-17 13:20
Data from the partner services programme in New York City suggests that gay men who have previously used an HIV self-test tend to seek confirmatory testing without delay, according to an article published online ahead of print in Sexually Transmitted Diseases. The study also highlights socio-demographic differences between those using